Sensitivity vs. standard of care criteria.

Specificity vs. standard of care criteria.

^{*Excluding samples with >20% blood}

The Synovasure Alpha Defensin Lateral Flow Test is a standalone, rapid device for detecting alpha defensin in synovial fluid. The test received FDA authorization in 2019 as a CLIA moderately complex test.

Results in 10 minutes following performance of test.

Demonstrates a high sensitivity (94.3%) and specificity (94.5%). In addition, results proven in clinical studies to be unaffected by:

• Prior antibiotic administration^,,

• Comorbidities related to inflammation^,,

• Type and/or virulence of the organism^,,

Only needs 15 microliters of synovial fluid to perform test.

• Infection Diagnostics

• Revision Knee 

• Revision Hip